FDAnews Drug Daily Bulletin
Pharmaceuticals / Inspections and Audits

Celgene Drops Crohn’s Disease Drug

Oct. 25, 2017
A A

Celgene abandoned development of its Crohn’s disease drug Revolve (mongersen) after disappointing results from a Phase III clinical trial.

The drug failed to pass muster in an interim futility analysis, the company said.

Celgene said it will continue development of other drugs for Crohn’s.

View today's stories